Analyzing MDxHealth (NASDAQ:MDXH) and Privia Health Group (NASDAQ:PRVA)

Privia Health Group (NASDAQ:PRVA) and MDxHealth (NASDAQ:MDXH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Privia Health Group and MDxHealth, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0	3	13	0	2.81
MDxHealth	1	0	4	0	2.60

Privia Health Group presently has a consensus price target of $30.50, suggesting a potential upside of 27.40%. MDxHealth has a consensus price target of $7.75, suggesting a potential upside of 104.49%. Given MDxHealth’s higher possible upside, analysts clearly believe MDxHealth is more favorable than Privia Health Group.

Institutional & Insider Ownership

94.5% of Privia Health Group shares are owned by institutional investors. 10.7% of Privia Health Group shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Privia Health Group has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Profitability

This table compares Privia Health Group and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Privia Health Group	0.89%	2.52%	1.47%
MDxHealth	-30.50%	-1,078.01%	-20.05%

Earnings and Valuation

This table compares Privia Health Group and MDxHealth”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$1.74 billion	1.70	$14.39 million	$0.13	184.15
MDxHealth	$90.05 million	1.99	-$38.07 million	($0.64)	-5.92

Privia Health Group has higher revenue and earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Summary

Privia Health Group beats MDxHealth on 11 of the 14 factors compared between the two stocks.

About Privia Health Group

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.